Pharmacokinetics of Citalopram in Relation to the Spar Oxidation Polymorphisms

Therapeutic Drug Monitoring

15, 11-17

DOI: 10.1097/00007691-199302000-00002

Citation Report

#	Article	IF	Citations
1	The pharmacogenetics of the selective serotonin reuptake inhibitors. The Clinical Investigator, 1993, 71, 1002-9.	0.6	79
2	Molecular basis of drug oxidation polymorphisms. Nordic Journal of Psychiatry, 1993, 47, 27-31.	0.7	0
3	Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. Journal of Pharmacological and Toxicological Methods, 1994, 31, 177-186.	0.3	59
4	Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications. Pharmacological Research, 1994, 29, 121-137.	3.1	16
5	Fluoxetine. New England Journal of Medicine, 1994, 331, 1354-1361.	13.9	193
6	The role of Sâ€mephenytoin 4'â€hydroxylase in imipramine metabolism by human liver microsomes: a twoâ€enzyme kinetic analysis of Nâ€•demethylation and 2â€hydroxylation.. British Journal of Clinical Pharmacology, 1994, 37, 237-242.	1.1	45
7	Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clinical Pharmacology and Therapeutics, 1994, 56, 176-183.	2.3	56
8	Interethnic Factors Important for Drug Development and Registration. Clinical Research and Regulatory Affairs, 1995, 12, 23-46.	2.1	1
9	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*. Clinical Pharmacology and Therapeutics, 1995, 57, 670-677.	2.3	101
10	Citalopram-lithium combination treatment of elderly depressed patients: A pilot study. International Journal of Geriatric Psychiatry, 1995, 10, 281-287.	1.3	20
11	Genetic analysis of the S-mephenytoin polymorphism in a chinese population*. Clinical Pharmacology and Therapeutics, 1995, 58, 404-411.	2.3	126
12	The effects of selective serotonin reuptake inhibitors and their metabolites on Sâ€mephenytoin 4'â€hydroxylase activity in human liver microsomes.. British Journal of Clinical Pharmacology, 1995, 40, 481-485.	1.1	71
13	â€œIt's the genes, stupidâ€•Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sciences, 1995, 56, 2285-2298.	2.0	146
14	The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy. Clinical Pharmacokinetics, 1996, 30, 107-140.	1.6	55
15	Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors???. Clinical Pharmacokinetics, 1996, 31, 444-469.	1.6	182
16	Polymorphic Drug Oxidation. CNS Drugs, 1996, 5, 200-223.	2.7	124
17	Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology, 1996, 128, 421-425.	1.5	66
18	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology, 1996, 51, 73-78.	0.8	284

#	Article	IF	Citations
19	Pharmacokinetics of Selective Serotonin Reuptake Inhibitors: Clinical Relevance. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 203-208.	0.0	74
20	Antidepressants and drugâ€metabolizing enzymes â€" expert group report. Acta Psychiatrica Scandinavica, 1996, 93, 71-79.	2.2	63
21	Psychiatry, psychopharmacology and P-450s. Human Psychopharmacology, 1996, 11, 97-114.	0.7	36
22	Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods. Biomedical Applications, 1996, 678, 73-92.	1.7	16
23	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*. Clinical Pharmacology and Therapeutics, 1996, 59, 322-331.	2.3	61
24	Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity*. Clinical Pharmacology and Therapeutics, 1996, 60, 183-190.	2.3	120
25	Genotyping of S-mephenytoin 4â€²-hydroxylation in an extended Japanese population*. Clinical Pharmacology and Therapeutics, 1996, 60, 661-666.	2.3	267
26	Venlafaxine oxidation in vitro is catalysed by CYP2D6. British Journal of Clinical Pharmacology, 1996, 41, 149-156.	1.1	208
27	Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions. Clinical Pharmacokinetics, 1997, 33, 454-471.	1.6	143
28	Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacokinetics, 1997, 32, 1-21.	1.6	315
30	Effects of genetic defects in the CYP2C19 gene on the Nâ€demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry and Clinical Neurosciences, 1997, 51, 253-257.	1.0	34
31	Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatrica Scandinavica, 1997, 96, 14-21.	2.2	84
32	Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Advanced Drug Delivery Reviews, 1997, 27, 171-199.	6.6	49
33	Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European Journal of Clinical Pharmacology, 1997, 52, 129-133.	0.8	70
34	Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. European Journal of Clinical Pharmacology, 1997, 52, 241-242.	0.8	27
35	Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. , 1997, 9, 686-692.		106
36	Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype*. Clinical Pharmacology and Therapeutics, 1998, 64, 391-401.	2.3	85
37	CYP2D6 polymorphism is not crucial for the disposition of selegiline*. Clinical Pharmacology and Therapeutics, 1998, 64, 402-411.	2.3	23

#	Article	IF	Citations
38	Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. European Journal of Clinical Pharmacology, 1998, 54, 237-242.	0.8	61
40	Metabolic Drug Interactions with Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants. Neuroscience and Biobehavioral Reviews, 1998, 22, 325-333.	2.9	29
41	Metabolism of the Newer Antidepressants. Clinical Pharmacokinetics, 1998, 34, 281-302.	1.6	155
42	Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica, 1998, 28, 1129-1165.	0.5	109
43	Pharmacogenetics of the hepatic cytochrome P450 enzyme system: its relevance for prescribing in psychiatry. Irish Journal of Psychological Medicine, 1998, 15, 96-99.	0.7	0
44	Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes. Pharmacology, 1999, 59, 298-309.	0.9	101
45	Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cellular and Molecular Neurobiology, 1999, 19, 443-466.	1.7	124
46	Polymorphic cytochromes P450 and drugs used in psychiatry. Cellular and Molecular Neurobiology, 1999, 19, 325-354.	1.7	43
47	Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. European Journal of Clinical Pharmacology, 1999, 54, 943-946.	0.8	25
48	CYP2D6 Mutations and Therapeutic Outcome in Schizophrenic Patients. Pharmacotherapy, 1999, 19, 1057-1063.	1.2	18
49	Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry. Pharmacotherapy, 1999, 19, 675-689.	1.2	39
50	Genetic Polymorphisms of HumanN-Acetyltransferase, Cytochrome P450, Glutathione-S-Transferase, and Epoxide Hydrolase Enzymes: Relevance to Xenobiotic Metabolism and Toxicity. Critical Reviews in Toxicology, 1999, 29, 59-124.	1.9	279
51	Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends in Pharmacological Sciences, 1999, 20, 342-349.	4.0	470
52	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biological Psychiatry, 1999, 46, 839-849.	0.7	80
53	Citalopram for treatment-resistant obsessive-compulsive disorder. European Psychiatry, 1999, 14, 101-106.	0.1	54
54	Lack of Interaction Between Citalopram and the CYP3A4 Substrate Triazolam. Pharmacotherapy, 2000, 20, 750-755.	1.2	14
55	Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, 85, 11-28.		666
56	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. International Journal of Neuropsychopharmacology, 2000, 3, 55-60.	1.0	19

#	Article	IF	Citations
57	Suicide Attempt by Pure Citalopram Overdose Causing Long-lasting Severe Sinus Bradycardia, Hypotension and Syncopes: Successful Therapy with a Temporary Pacemaker. Pharmacopsychiatry, 2000, 33, 150-152.	1.7	39
58	Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics, 2000, 1, 125-151.	0.6	106
59	THE INFLUENCE OF ETHNICITY AND ANTIDEPRESSANT PHARMACOGENETICS IN THE TREATMENT OF DEPRESSION. Drug Metabolism and Drug Interactions, 2000, 16, 39-68.	0.3	31
60	Effect of citalopram on plasma levels of oral theophylline. Clinical Therapeutics, 2000, 22, 1494-1501.	1.1	19
61	Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. European Neuropsychopharmacology, 2001, 11, 275-283.	0.3	121
62	Drug Interactions between Psychoactive Agents and Antiepileptic Agents. Epilepsy and Behavior, 2001, 2, 92-105.	0.9	2
63	Diphenhydramine Alters the Disposition of Venlafaxine Through Inhibition of CYP2D6 Activity in Humans. Journal of Clinical Psychopharmacology, 2001, 21, 175-184.	0.7	72
64	Lack of Effect of Citalopram on the Steady-State Pharmacokinetics of Carbamazepine in Healthy Male Subjects. Journal of Clinical Psychopharmacology, 2001, 21, 493-499.	0.7	25
65	Enantioselective Analysis of Citalopram and Metabolites in Adolescents. Therapeutic Drug Monitoring, 2001, 23, 658-664.	1.0	43
66	Lack of Citalopram Effect on Oral Digoxin Pharmacokinetics. Journal of Clinical Pharmacology, 2001, 41, 340-346.	1.0	22
67	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:â€¨a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica, 2001, 104, 173-192.	2.2	367
68	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology, 2001, 52, 349-355.	1.1	530
69	Lack of Effect of a Single Dose of Ketoconazole on the Pharmacokinetics of Citalopram. Pharmacotherapy, 2001, 21, 163-168.	1.2	22
70	Oxcarbazepine in Affective and Schizoaffective Disorders. Pharmacopsychiatry, 2001, 34, 242-250.	1.7	203
72	Serum Levels of Citalopram and Its Main Metabolites in Adolescent Patients Treated in a Naturalistic Clinical Setting. Journal of Clinical Psychopharmacology, 2002, 22, 406-413.	0.7	23
73	Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics and Genomics, 2002, 12, 703-711.	5.7	123
74	Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update. Current Drug Metabolism, 2002, 3, 13-37.	0.7	334
75	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. European Neuropsychopharmacology, 2002, 12, 255-260.	0.3	51

#	Article	IF	Citations
76	Enantiomers' potential in psychopharmacologyâ€"a critical analysis with special emphasis on the antidepressant escitalopram. European Neuropsychopharmacology, 2002, 12, 433-444.	0.3	79
77	Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clinical Pharmacokinetics, 2002, 41, 913-958.	1.6	771
78	Clinical implications of CYP2C19 polymorphism for tailor-made pharmacotherapy. International Congress Series, 2002, 1244, 41-49.	0.2	1
79	Pharmacogenetics of chiral psychotropic drugs. , 2002, , 181-214.		4
80	Metabolic drug interactions with new psychotropic agents. Fundamental and Clinical Pharmacology, 2003, 17, 517-538.	1.0	152
81	Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. British Journal of Clinical Pharmacology, 2003, 56, 415-421.	1.1	79
82	Escitalopram. CNS Drugs, 2003, 17, 343-362.	2.7	114
83	Clinical Pharmacokinetics of Oxcarbazepine. Clinical Pharmacokinetics, 2003, 42, 1023-1042.	1.6	190
84	Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 85-102.	2.5	495
85	Role of Pharmacogenomics in Individualising Treatment with SSRIs. CNS Drugs, 2003, 17, 143-151.	2.7	45
86	PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19. Drug Metabolism and Disposition, 2003, 31, 1255-1259.	1.7	77
87	Ethnic and Geographical Distributions of CYP2C19 Alleles in the Populations of Southeast Asia. Advances in Experimental Medicine and Biology, 2003, 531, 37-46.	0.8	12
88	A CYP2D6 Phenotype-Genotype Mismatch in Japanese Psychiatric Patients. Pharmacopsychiatry, 2003, 36, 192-196.	1.7	16
89	Antidepressant Drugs in the Elderly â€" RÃ1e of the Cytochrome P450 2D6. World Journal of Biological Psychiatry, 2003, 4, 74-80.	1.3	13
90	Individualized Medicine - Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders. Pharmacopsychiatry, 2003, 36, 235-243.	1.7	40
92	Therapeutic Drug Monitoring of Racemic Citalopram: A 5-Year Experience in Sweden, 1992â€"1997. Therapeutic Drug Monitoring, 2003, 25, 183-191.	1.0	58
93	Routine Therapeutic Drug Monitoring in Patients Treated with 10-360 mg/day Citalopram. Therapeutic Drug Monitoring, 2003, 25, 600-608.	1.0	31
94	Enantioselective Analysis of Citalopram and its Metabolites in Postmortem Blood and Genotyping For CYD2D6 and CYP2C19. Journal of Analytical Toxicology, 2004, 28, 94-104.	1.7	48

#	Article	IF	Citations
95	Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 2004, 9, 442-473.	4.1	661
96	Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 231-5.	1.8	63
97	Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. European Journal of Clinical Pharmacology, 2004, 60, 329-36.	0.8	143
98	Increased liability of tramadol?warfarin interaction in individuals with mutations in the cytochrome P 450 2D6 gene. European Journal of Clinical Pharmacology, 2004, 60, 369-72.	0.8	28
99	Antidepressants: Past, Present and Future. Handbook of Experimental Pharmacology, 2004, , .	0.9	21
100	Citalopram as Treatment of Depression in Patients With Epilepsy. Clinical Neuropharmacology, 2004, 27, 133-136.	0.2	138
101	Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants. Therapie, 2004, 59, 5-12.	0.6	79
102	Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clinical Pharmacology and Therapeutics, 2005, 78, 559-581.	2.3	110
103	ORIGINAL RESEARCHâ€"EJACULATORY DISORDERS: Serum Antioxidant Enzymes and Malondialdehyde Levels in Patients with Premature Ejaculation Before and After Pharmacotherapy. Journal of Sexual Medicine, 2005, 2, 254-258.	0.3	2
105	The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 571-605.	0.8	65
107	Phenotype-genotype Relationship and Clinical Effects of Citalopram in Chinese Patients. Journal of Clinical Psychopharmacology, 2006, 26, 367-372.	0.7	43
108	Heterozygous Mutation in CYP2C19 Significantly Increases the Concentration/Dose Ratio of Racemic Citalopram and Escitalopram (S-citalopram). Therapeutic Drug Monitoring, 2006, 28, 102-105.	1.0	49
109	The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 287-293.	1.8	31
110	Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation. Journal of Human Genetics, 2006, 51, 118-123.	1.1	5
112	Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacological Reviews, 2006, 58, 521-590.	7.1	379
113	The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 21-31.	1.5	39
114	Therapeutic Drug Monitoring of Escitalopram in an Outpatient Setting. Therapeutic Drug Monitoring, 2007, 29, 758-766.	1.0	40
115	Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Pharmacogenetics and Genomics, 2007, 17, 103-114.	0.7	18

#	Article	IF	Citations
116	Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects. Clinical Pharmacology and Therapeutics, 2007, 82, 606-609.	2.3	80
117	Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. European Journal of Clinical Pharmacology, 2008, 64, 1181-1188.	0.8	73
118	Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients. Clinical Pharmacology and Therapeutics, 2008, 83, 322-327.	2.3	195
119	Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. British Journal of Clinical Pharmacology, 2008, 65, 767-774.	1.1	129
120	PhRMA White Paper on ADME Pharmacogenomics. Journal of Clinical Pharmacology, 2008, 48, 849-889.	1.0	62
121	Pharmacogenetics-Guided Dose Modifications of Antidepressants. Clinics in Laboratory Medicine, 2008, 28, 619-626.	0.7	39
122	Drug-Drug Interactions, Second Edition. , 0, , .		8
123	Identification of a Novel CYP2C19-Mediated Metabolic Pathway ofS-Citalopram in Vitro. Drug Metabolism and Disposition, 2009, 37, 2340-2348.	1.7	12
124	Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. European Journal of Clinical Pharmacology, 2009, 65, 887-894.	0.8	37
125	Enantioselective Analysis of Citalopram and Escitalopram in Postmortem Blood Together with Genotyping for CYP2D6 and CYP2C19. Journal of Analytical Toxicology, 2009, 33, 65-76.	1.7	12
126	Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews, 2009, 41, 89-295.	1.5	671
127	Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy. Clinical Pharmacokinetics, 2009, 48, 677-683.	1.6	84
128	Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Medicine, 2009, 1, 10.	3.6	33
129	Cytochrome P450 2D6 Genotyping. CNS Drugs, 2009, 23, 181-191.	2.7	33
130	Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain. Clinical Pharmacology and Therapeutics, 2009, 86, 626-633.	2.3	24
132	Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. European Journal of Pharmacology, 2010, 626, 200-204.	1.7	43
133	Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. Journal of Medicinal Chemistry, 2010, 53, 7902-7917.	2.9	1,279
134	Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics Journal, 2011, 11, 359-367.	0.9	54

#	Article	IF	Citations
135	CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics, 2011, 21, 1-9.	0.7	126
136	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 769-772.	0.7	53
137	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmacy, 2011, 33, 3-9.	1.0	19
138	Cytochrome p450â€dependent disposition of the enantiomers of citalopram and its metabolites: In vivo studies in Sprague–Dawley and Dark Agouti rats. Chirality, 2011, 23, 172-177.	1.3	8
139	CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psychopharmacology, 2012, 26, 398-407.	2.0	69
141	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmacy, 2013, 35, 369-375.	1.0	16
142	A review of the interplay between tuberculosis and mental health. General Hospital Psychiatry, 2013, 35, 398-406.	1.2	107
143	Pharmacokinetics and Bioavailability Comparison of Generic and Branded Citalopram 20Âmg Tablets. Clinical Drug Investigation, 2013, 33, 1-9.	1.1	13
144	Cardiotoxicity in a Citalopram and Olanzapine Overdose. Journal of Emergency Medicine, 2013, 45, 554-558.	0.3	16
145	Psychiatric Morbidity and Other Factors Affecting Treatment Adherence in Pulmonary Tuberculosis Patients. Tuberculosis Research and Treatment, 2013, 2013, 1-37.	0.2	105
146	Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 504-511.	0.7	6
147	Heterologous expression of human cytochrome P450 (CYP) 2C19 in Escherichia coli and establishment of RP–HPLC method to serve as activity marker. Biomedical Chromatography, 2013, 27, 859-865.	0.8	9
148	Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Frontiers in Genetics, 2012, 3, 318.	1.1	59
149	Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment, 2014, 10, 1161.	1.0	27
150	Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area. Current Psychiatry Reviews, 2014, 10, 118-132.	0.9	13
151	Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. Clinical Pharmacokinetics, 2014, 53, 801-811.	1.6	69
152	Citalopram and escitalopram plasma drug and metabolite concentrations: genome–wide associations. British Journal of Clinical Pharmacology, 2014, 78, 373-383.	1.1	67
153	Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. European Journal of Clinical Pharmacology, 2014, 70, 933-940.	0.8	40

#	Article	IF	Citations
154	Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Medicine, 2014, 12, 90.	2.3	23
155	Renal Excretion of Xenobiotics and Estimation of Related PK/TK Parameters and Constants. , 2015, , 134-171.		0
156	The impact ofCYP2C19polymorphisms on citalopram metabolism in patients with major depressive disorder. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 672-679.	0.7	14
157	Melatonin Interaction Resulting in Severe Sedation. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 124.	0.9	16
158	Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription. Current Drug Metabolism, 2015, 16, 17-45.	0.7	10
159	Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. Drug Metabolism and Personalized Therapy, 2015, 30, 147-163.	0.3	6
160	Clinical pharmacy service practice in a Chinese tertiary hospital. Drug Metabolism and Personalized Therapy, 2015, 30, 215-230.	0.3	8
161	Citalopram-Induced Long QT Syndrome and the Mammalian Dive Reflex. Drug Safety - Case Reports, 2015, 2, 12.	0.9	11
162	Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2016, 44, 1217-1228.	1.7	5
163	Pharmacokinetics of serotonergic drugs: focus on OCD. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 261-273.	1.5	8
164	Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations. Journal of Clinical Pharmacology, 2020, 60, 477-488.	1.0	8
165	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
166	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Psychiatry, 2021, 22, 561-628.	1.3	17
167	Polypharmazie in der Konsiliar- und Liaisonpsychiatrie. , 2006, , 173-195.		1
168	Polypharmazie in der Konsiliar-und Liaisonpsychiatrie. , 2009, , 189-214.		1
169	Organische psychische StÃ¶rungen bei wichtigen somatischen Erkrankungen. , 2008, , 1111-1141.		4
170	General Principles of Pharmacokinetics. Handbook of Experimental Pharmacology, 2004, , 35-86.	0.9	4
171	HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. , 2009, , 225-238.		1

#	Article	IF	Citations
172	The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.. Journal of Biological Chemistry, 1994, 269, 15419-15422.	1.6	818
173	A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive Patients. Journal of Clinical Psychopharmacology, 1996, 16, 307-314.	0.7	156
174	Cardiac Safety of Citalopram: Prospective Trials and Retrospective Analyses. Journal of Clinical Psychopharmacology, 1999, 19, 407-415.	0.7	85
175	Human Cytochromes and Some Newer Antidepressants: Kinetics, Metabolism, and Drug Interactions. Journal of Clinical Psychopharmacology, 1999, 19, 23S-35S.	0.7	82
176	The Effect of Age and Concomitant Treatment with Other Psychoactive Drugs on Serum Concentrations of Citalopram Measured with a Nonenantioselective Method. Therapeutic Drug Monitoring, 1996, 18, 111-117.	1.0	45
177	A Dual Label Oligonucleotide Ligation Assay for Detection of theCYP2C19*1, CYP2C19*2, and CYP2C19*3 Alleles Involving Time-Resolved Fluorometry. Therapeutic Drug Monitoring, 1998, 20, 1-6.	1.0	15
178	Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine. Therapeutic Drug Monitoring, 1998, 20, 7-13.	1.0	22
179	High-Performance Liquid Chromatography Method for Analyzing Citalopram and Desmethylcitalopram From Human Serum. Therapeutic Drug Monitoring, 1998, 20, 25-29.	1.0	44
180	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. Therapeutic Drug Monitoring, 1999, 21, 263.	1.0	9
181	Is Therapeutic Drug Monitoring a Case for Optimizing Clinical Outcome and Avoiding Interactions of the Selective Serotonin Reuptake Inhibitors?. Therapeutic Drug Monitoring, 2000, 22, 143-154.	1.0	115
182	Stereoselective HPLC-Assay for Citalopram and Its Metabolites. Therapeutic Drug Monitoring, 2000, 22, 219-224.	1.0	52
184	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. Frontiers in Genetics, 2020, 11, 491895.	1.1	28
185	Changes in Antidepressant Metabolism and Dosing Across Pregnancy and Early Postpartum. Journal of Clinical Psychiatry, 2008, 69, 652-658.	1.1	125
186	Treatment of Comorbid Tuberculosis and Depression. Primary Care Companion To the Journal of Clinical Psychiatry, 2001, 3, 236-243.	0.6	35
187	Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. , 2002, , 37-50.		0
189	Drug-Metabolizing Enzymes and P-Glycoprotein. , 2004, , 43-67.		0
190	Interethnic Differences in Drug Response. Drugs and the Pharmaceutical Sciences, 2005, , 221-246.	0.1	2
191	Pharmacokinetics, Clinical Effect and Side Effect of New Antidepressants, SSRI: 3. Pharmacogenetics of Selective Serotonin Reuptake Inhibitors. Japanese Journal of Clinical Pharmacology and Therapeutics, 2006, 37, 265-272.	0.1	0

#	Article	IF	Citations
192	Drug-Metabolizing Enzymes. , 2009, , 85-117.		0
195	Relationship between Phenotype and Genotype of CYP2C19 Using a Simplified Method for Phenotyping with Omeprazole in Healthy Japanese.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1998, 29, 495-505.	0.1	0
196	Uso de citalopram para trastorno obsesivo-compulsivo resistente al tratamiento. European Psychiatry (Ed EspaÃ±ola), 1999, 6, 441-447.	0.0	0
197	Konsiliar- und Liaisonpsychiatrie. , 2016, , 187-208.		0
198	Mammalian CYP2D Members. , 2016, , 101-138.		0
199	Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers after Oral vs. Infusion Citalopram Therapy in Dextromethorphan- and Mephenytoin-Phenotyped Patients with Major Depression. Therapeutic Drug Monitoring, 2020, Publish Ahead of Print, 436-442.	1.0	1
202	Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants. Genetica, 0, , .	0.5	0
204	Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers. Therapeutic Drug Monitoring, 2022, 44, 720-728.	1.0	2
205	Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes. Pharmaceutics, 2022, 14, 2833.	2.0	2